Analysts Set Vor Biopharma Inc. (NASDAQ:VOR) Price Target at $42.25

Vor Biopharma Inc. (NASDAQ:VOR) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $42.25.

A number of research firms recently commented on VOR. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings cut Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective on the stock.

Insider Buying and Selling at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the sale, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 3,002,903 shares of company stock valued at $49,412,176 over the last quarter. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. grew its position in Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. grew its position in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after buying an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Vor Biopharma during the 4th quarter worth $33,275,000. Paradigm Biocapital Advisors LP bought a new position in shares of Vor Biopharma during the 4th quarter worth $22,890,000. Finally, NEXTBio Capital Management LP bought a new position in shares of Vor Biopharma during the 4th quarter worth $13,080,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Up 7.8%

Shares of NASDAQ:VOR opened at $16.10 on Friday. The stock has a 50 day moving average of $14.77 and a 200 day moving average of $14.37. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, research analysts expect that Vor Biopharma will post -2.51 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).